Lipella pharmaceuticals initiates phase 2a trial for lp-310 in oral lichen planus, enrolls first patients

Pittsburgh, july 29, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center phase 2a clinical trial evaluating lp-310 for the treatment of oral lichen planus (olp). this chronic inflammatory condition, which affects over 6 million americans, is characterized by mouth mucous membrane inflammation, pain, and ulceration, and lacks fda-approved treatments.
LIPO Ratings Summary
LIPO Quant Ranking